We identify disease-relevant immune targets using chemical biology approaches, including small-molecule-based profiling and covalent probes.
By focusing on druggability, cell-type specificity, and functional relevance, we prioritize targets that can be directly translated into therapeutic strategies.

We develop precision molecular tools, including targeted protein degraders (PROTACs) and covalent modulators, to control immune signaling pathways.
Our strategies emphasize cell-type selectivity, spatio-temporal control, and mechanistic clarity, enabling functional dissection and therapeutic intervention. 

By integrating target discovery and precise protein modulation, we aim to reprogram immune responses in cancer and immune-mediated diseases.
Our ultimate goal is to develop next-generation immunotherapies with improved specificity and reduced systemic toxicity.